Literature DB >> 27122594

Renal Function and Tenofovir Disoproxil Fumarate for Preexposure Prophylaxis: How Safe Is Safe Enough?

Douglas S Krakower1, Kenneth H Mayer1.   

Abstract

Entities:  

Keywords:  HIV prevention; nephrotoxicity; preexposure prophylaxis; proximal tubules; tenofovir disoproxil fumarate

Mesh：

Substances：

Year:  2016        PMID： 27122594      PMCID： PMC5021225          DOI： 10.1093/infdis/jiw169

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  12 in total

1.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Authors:  Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden
Journal:  N Engl J Med       Date:  2010-11-23       Impact factor: 91.245

Review 2.  Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients.

Authors:  Ryan D Cooper; Natasha Wiebe; Nathaniel Smith; Philip Keiser; Saraladevi Naicker; Marcello Tonelli
Journal:  Clin Infect Dis       Date:  2010-09-01       Impact factor: 9.079

3.  Antiretroviral preexposure prophylaxis for HIV prevention.

Authors:  Michael C Thigpen; Charles E Rose; Lynn A Paxton
Journal:  N Engl J Med       Date:  2013-01-03       Impact factor: 91.245

4.  Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

Authors:  Paul E Sax; David Wohl; Michael T Yin; Frank Post; Edwin DeJesus; Michael Saag; Anton Pozniak; Melanie Thompson; Daniel Podzamczer; Jean Michel Molina; Shinichi Oka; Ellen Koenig; Benoit Trottier; Jaime Andrade-Villanueva; Gordon Crofoot; Joseph M Custodio; Andrew Plummer; Lijie Zhong; Huyen Cao; Hal Martin; Christian Callebaut; Andrew K Cheng; Marshall W Fordyce; Scott McCallister
Journal:  Lancet       Date:  2015-04-15       Impact factor: 79.321

5.  On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

Authors:  Jean-Michel Molina; Catherine Capitant; Bruno Spire; Gilles Pialoux; Laurent Cotte; Isabelle Charreau; Cecile Tremblay; Jean-Marie Le Gall; Eric Cua; Armelle Pasquet; François Raffi; Claire Pintado; Christian Chidiac; Julie Chas; Pierre Charbonneau; Constance Delaugerre; Marie Suzan-Monti; Benedicte Loze; Julien Fonsart; Gilles Peytavin; Antoine Cheret; Julie Timsit; Gabriel Girard; Nicolas Lorente; Marie Préau; James F Rooney; Mark A Wainberg; David Thompson; Willy Rozenbaum; Veronique Doré; Lucie Marchand; Marie-Christine Simon; Nicolas Etien; Jean-Pierre Aboulker; Laurence Meyer; Jean-François Delfraissy
Journal:  N Engl J Med       Date:  2015-12-01       Impact factor: 91.245

6.  Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials.

Authors:  Rabi Yacoub; Girish N Nadkarni; Damian Weikum; Ioannis Konstantinidis; Anna Boueilh; Robert M Grant; Kenneth K Mugwanya; Jared M Baeten; Christina M Wyatt
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-01       Impact factor: 3.731

7.  No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting.

Authors:  Jonathan E Volk; Julia L Marcus; Tony Phengrasamy; Derek Blechinger; Dong Phuong Nguyen; Stephen Follansbee; C Bradley Hare
Journal:  Clin Infect Dis       Date:  2015-09-01       Impact factor: 9.079

8.  Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.

Authors:  Kenneth Mugwanya; Jared Baeten; Connie Celum; Deborah Donnell; Thomas Nickolas; Nelly Mugo; Andrea Branch; Jordan Tappero; James Kiarie; Allan Ronald; Michael Yin; Christina Wyatt
Journal:  J Infect Dis       Date:  2016-03-29       Impact factor: 5.226

9.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Kachit Choopanya; Michael Martin; Pravan Suntharasamai; Udomsak Sangkum; Philip A Mock; Manoj Leethochawalit; Sithisat Chiamwongpaet; Praphan Kitisin; Pitinan Natrujirote; Somyot Kittimunkong; Rutt Chuachoowong; Roman J Gvetadze; Janet M McNicholl; Lynn A Paxton; Marcel E Curlin; Craig W Hendrix; Suphak Vanichseni
Journal:  Lancet       Date:  2013-06-13       Impact factor: 79.321

10.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

Authors:  Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill
Journal:  Lancet       Date:  2015-09-09       Impact factor: 79.321
View more
  1 in total

Review 1.  Lessons from a decade of voluntary medical male circumcision implementation and their application to HIV pre-exposure prophylaxis scale up.

Authors:  Jason B Reed; Rupa R Patel; Rachel Baggaley
Journal:  Int J STD AIDS       Date:  2018-08-16       Impact factor: 1.359
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.